The Health Economics of Bladder Cancer: An Updated Review of the Published Literature

[1]  Y. Lotan,et al.  The economics of bladder cancer: costs and considerations of caring for this disease. , 2014, European urology.

[2]  C. Seideman,et al.  Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. , 2013, The Journal of urology.

[3]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[4]  T. Athanasiou,et al.  Outpatient laser ablation of non‐muscle‐invasive bladder cancer: is it safe, tolerable and cost‐effective? , 2013, BJU international.

[5]  S. Malkowicz,et al.  Bladder preservation in the treatment of muscle‐invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy , 2013, BJU international.

[6]  John L. Gore,et al.  The costs of non-muscle invasive bladder cancer. , 2013, The Urologic clinics of North America.

[7]  E. Steyerberg,et al.  FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies. , 2013, The Journal of urology.

[8]  J. McKiernan,et al.  418 COST EFFECTIVENESS ANALYSIS OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER , 2013 .

[9]  David A. Green,et al.  Cost‐effective treatment of low‐risk carcinoma not invading bladder muscle , 2013, BJU international.

[10]  J. McKiernan,et al.  Cost-effectiveness analysis of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Castle,et al.  Cost Analysis of Open Radical Cystectomy Versus Robot-assisted Radical Cystectomy , 2013, Current Urology Reports.

[12]  D. Globe,et al.  Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. , 2012, The Journal of urology.

[13]  A. Carter,et al.  A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding , 2012, BMC Public Health.

[14]  S. Lipsitz,et al.  Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. , 2012, European urology.

[15]  S. Boorjian,et al.  The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. , 2012, The Journal of urology.

[16]  Anirban P. Mitra,et al.  A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer , 2012, BJU international.

[17]  S. Shariat,et al.  The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy , 2011, BJU international.

[18]  B. V. van Rhijn.  PROSPECTIVE TRIAL TO IDENTIFY OPTIMAL BLADDER CANCER SURVEILLANCE PROTOCOL: REDUCING COSTS WHILE MAXIMIZING SENSITIVITY , 2011, BJU international.

[19]  Jung-Der Wang,et al.  Estimation of benefit of prevention of occupational cancer for comparative risk assessment: methods and examples , 2011, Occupational and Environmental Medicine.

[20]  S. Shariat,et al.  Cost‐analysis comparison of robot‐assisted laparoscopic radical cystectomy (RC) vs open RC , 2011, BJU international.

[21]  E. Castle,et al.  Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis. , 2011, Urology.

[22]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[23]  R. Chou,et al.  Screening Adults for Bladder Cancer , 2010 .

[24]  W. Sexton,et al.  Bladder cancer: a review of non-muscle invasive disease. , 2010, Cancer control : journal of the Moffitt Cancer Center.

[25]  M. Kuczyk,et al.  Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. , 2010, International braz j urol : official journal of the Brazilian Society of Urology.

[26]  J. Brophy,et al.  Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. , 2010, Urology.

[27]  Charles L. Bennett,et al.  The excessive cost of early stage bladder cancer care , 2010, Cancer.

[28]  F. Brimo,et al.  Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. , 2010, Urology.

[29]  S. Taneja,et al.  The effect of changes in Medicare reimbursement on the practice of office and hospital‐based endoscopic surgery for bladder cancer , 2010, Cancer.

[30]  E. Wallen,et al.  Cost analysis of robotic versus open radical cystectomy for bladder cancer. , 2010, The Journal of urology.

[31]  Yair Lotan,et al.  Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. , 2010, European urology.

[32]  A. Finelli,et al.  Cost‐effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette‐Guerin therapy for high‐risk, high‐grade (T1G3) bladder cancer , 2009, Cancer.

[33]  P. Fayers,et al.  Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion--a prospective cohort study with a systematic review of literature. , 2009, Urology.

[34]  Youngmee Kim,et al.  Time costs associated with informal caregiving for cancer survivors , 2009, Cancer.

[35]  Edward M Messing,et al.  Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria , 2009, BMC urology.

[36]  E. Steyerberg,et al.  Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? , 2009, BJU international.

[37]  E. Messing,et al.  Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? , 2009, Cancer.

[38]  J. Birkmeyer,et al.  Provider treatment intensity and outcomes for patients with early-stage bladder cancer. , 2009, Journal of the National Cancer Institute.

[39]  S. Strope,et al.  Patterns of care for early stage bladder cancer , 2009, Cancer.

[40]  S. Krein,et al.  Understanding the variation in treatment intensity among patients with early stage bladder cancer , 2009, Cancer.

[41]  D. Schilling,et al.  Economic aspects of bladder cancer: what are the benefits and costs? , 2009, World Journal of Urology.

[42]  P. Rao,et al.  Routine perioperative chemotherapy instillation with initial bladder tumor resection , 2009, Cancer.

[43]  L. Kiemeney,et al.  The present and future burden of urinary bladder cancer in the world , 2009, World Journal of Urology.

[44]  R. Knuechel,et al.  Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? , 2009, Clinical medicine. Oncology.

[45]  D. Penson,et al.  Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. , 2008, The Journal of urology.

[46]  M. Grasso.  Bladder Cancer: A Major Public Health Issue , 2008 .

[47]  Angela Mariotto,et al.  Cost of care for elderly cancer patients in the United States. , 2008, Journal of the National Cancer Institute.

[48]  B. Davies,et al.  Effect of postcystectomy infectious complications on cost, length of stay, and mortality. , 2008, Urology.

[49]  P. Sweeney,et al.  URINE CYTOLOGY IN THE EVALUATION OF UROLOGICAL MALIGNANCY REVISITED-IS IT STILL NECESSARY? , 2008 .

[50]  K. Sethia,et al.  Is routine urine cytology useful in the haematuria clinic? , 2008, Annals of the Royal College of Surgeons of England.

[51]  A. Sabichi,et al.  Clinical model of cost of bladder cancer in the elderly. , 2008, Urology.

[52]  E. Park,et al.  The economic burden of cancer in Korea in 2002. , 2008, European journal of cancer care.

[53]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[54]  M. Brausi,et al.  The use of local anesthesia with N-DO injector (Physion) for transurethral resection (TUR) of bladder tumors and bladder mapping: preliminary results and cost-effectiveness analysis. , 2007, European urology.

[55]  E. Sacco,et al.  The cost of treatment and follow-up of bladder cancer in Italy. , 2007, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[56]  A. Finelli,et al.  Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis , 2007, PLoS medicine.

[57]  Stefano Galli,et al.  A cost comparison of laparoscopic versus open radical cystoprostatectomy and orthotopic ileal neobladder at a single institution. , 2007, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[58]  Maximilian Burger,et al.  Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. , 2007, European urology.

[59]  Badrinath R Konety,et al.  Bladder and upper tract urothelial cancer. , 2007, The Journal of urology.

[60]  W. See.  Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis , 2007 .

[61]  E. Messing.  Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. , 2007, European urology.

[62]  M. Miyazato,et al.  Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. , 2007, Urology.

[63]  E. Lamont,et al.  Patient time costs associated with cancer care. , 2007, Journal of the National Cancer Institute.

[64]  E. Messing,et al.  Long‐term outcome of hematuria home screening for bladder cancer in men , 2006, Cancer.

[65]  A. Sabichi,et al.  Clinical model of lifetime cost of treating bladder cancer and associated complications. , 2006, Urology.

[66]  Y. Lotan,et al.  Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. , 2006, Urologic oncology.

[67]  B. Konety,et al.  Influence of post-cystectomy complications on cost and subsequent outcome. , 2006, The Journal of urology.

[68]  B. Konety,et al.  Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer: data from the surveillance, epidemiology, and end results program. , 2005, The Journal of urology.

[69]  S. Holmäng,et al.  Costs of radical cystectomy , 2005, Scandinavian journal of urology and nephrology.

[70]  Vijay K Sangar,et al.  The economic consequences of prostate and bladder cancer in the UK , 2005, BJU international.

[71]  B. Konety,et al.  Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper? , 2004, The Journal of urology.

[72]  L. Lund,et al.  Holmium:YAG laser vaporization of recurrent papillary tumours of the bladder under local anaesthesia , 2004, BJU international.

[73]  Badrinath R Konety,et al.  Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs. , 2004, Urology.

[74]  M. Aristides,et al.  Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer , 2004, Expert review of pharmacoeconomics & outcomes research.

[75]  M. Stöckle,et al.  Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. , 2003, Critical reviews in oncology/hematology.

[76]  Christopher J Kane,et al.  Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. , 2002, The Journal of urology.

[77]  S. Holmäng,et al.  The Cost of Bladder Tumour Treatment and Follow-up , 2002, Scandinavian journal of urology and nephrology.

[78]  G. Steinberg,et al.  Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma. , 2001, Urology.

[79]  P. Carroll,et al.  Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. , 2001, Urology.

[80]  D. Theodorescu,et al.  Impact of second opinion pathology in the definitive management of patients with bladder carcinoma , 2001, Cancer.

[81]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  B. Malavaud,et al.  Complications for Radical Cystectomy , 2000, European Urology.

[83]  R Sylvester,et al.  The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. , 2000, The Journal of urology.

[84]  L. Valiquette,et al.  Economic evaluation of NMP22 in the management of bladder cancer. , 2000, The Canadian journal of urology.

[85]  D. Redelmeier,et al.  Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. , 2000, The Journal of urology.

[86]  R. Hiatt,et al.  Problems in Assessing Screening Experience in Observational Studies of Screening Efficacy: Example of Urinalysis Screening for Bladder Cancer , 1995, Journal of medical screening.

[87]  L. Kessler,et al.  Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis , 1995, Medical care.

[88]  E. Messing,et al.  Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. , 1995, Urology.

[89]  D. Paulson,et al.  Complications of radical cystectomy and urinary diversion: a retrospective review of 675 cases in 2 decades. , 1992, The Journal of urology.

[90]  B. Armstrong,et al.  Bladder cancer screening among primary aluminum production workers in Quebec. , 1990, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[91]  R. E. Greenfield,et al.  An assessment of the impact of urine cytology screening using a computer-based model of bladder cancer. , 1984, The Urologic clinics of North America.

[92]  Seok-Jun Yoon,et al.  The economic burden of cancer in Korea in 2009. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[93]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[94]  Y. Lotan,et al.  Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines , 2013, International Archives of Occupational and Environmental Health.

[95]  Yair Lotan,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. , 2013, European urology.

[96]  Geoffrey E. Wile,et al.  Bladder cancer. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[97]  M. Soloway.  ICUD-EAU International Consultation on Bladder Cancer 2012: Recommendations on bladder cancer-progress in a cancer that lacks the limelight. , 2013, European urology.

[98]  C. Pashos,et al.  The health economics of bladder cancer , 2012, PharmacoEconomics.

[99]  R. Dhir.  Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker , 2010 .

[100]  R. Loo,et al.  National practice recommendations for hematuria: how to evaluate in the absence of strong evidence? , 2009, The Permanente journal.

[101]  Arnulf Stenzl,et al.  Guidelines on Bladder Cancer Muscle-invasive and Metastatic , 2008 .

[102]  Yair Lotan,et al.  Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.

[103]  J. Richie,et al.  Bladder cancer. Clinical practice guidelines in oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[104]  A. Mariani,et al.  Is cytology required for a hematuria evaluation? , 2004, The Journal of urology.

[105]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[106]  C. Roehrborn,et al.  Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. , 2002, The Journal of urology.

[107]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[108]  B. Malavaud,et al.  Complications for radical cystectomy. Impact of the American Society of Anesthesiologists score. , 2001, European urology.

[109]  N. Neymark.  The Economic Burden of Cancer , 1998 .

[110]  W. Zontine.  The urinary bladder. , 1975, Modern veterinary practice.